Navigation Links
Shengtai Pharmaceutical, Inc. Reports Financial Results for the Third Quarter and the First Nine Months of Fiscal Year 2010
Date:5/17/2010

WEIFANG, China, May 17 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported its financial results for the third quarter and the first nine months of fiscal year 2010 ended March 31, 2010.

    Financial Summary of the Third Quarter 2010
    -- Revenues totaled $29.41 million
    -- Net income totaled $0.98 million
    -- Basic and diluted earnings per share of $0.05
    -- Cash and restricted cash position at $18.10 million on March 31, 2010

    Financial Summary of the First Nine Months 2010
    -- Revenues totaled $81.04 million
    -- Net income totaled $2.81 million
    -- Basic and diluted earnings per share of $0.15
    -- Operating cash flow of $7.35 million

"Our company continued to reap good sales revenue in the third quarter of fiscal year 2010," said Mr. Qingtai Liu, Shengtai's CEO. "The operations of the third quarter added another $0.05 earnings per share to that of the previous two quarters, and delivered $0.15 of the total earnings per share for the nine months ended March 31, 2010."

Financial Results of the Third Quarter Fiscal 2010

Net sales for the three months ended March 31, 2010 were $29,407,287, an increase of $13,105,765, or 80.40%, compared with the same period in 2009. The increase in net sales primarily resulted from the increase of the Company's sales volume and se
'/>"/>

SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Shengtai Pharmaceutical, Inc Announces Appointment of New Chief Financial Officer
2. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
3. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
4. National Pharmaceutical Council Welcomes New Member, Otsuka America Pharmaceutical, Inc.
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... OTTAWA , Dec. 24, 2014 /CNW/ - ... Superburn" is being recalled after Health Canada tests confirmed ... serious health risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire ... is recalling the product from retail stores across ... body building purposes, including for weight loss and increased ...
(Date:12/24/2014)... Dec. 24, 2014  Novastem, a leader in ... patient in its study for ischemic stroke at ... Association, ischemic strokes account for 87 percent of ... patients in the study, entitled "Internal Research Protocol ... Mesenchymal Stem Cells and Intrathecal Administration of Neural ...
(Date:12/24/2014)...  Actavis plc (NYSE: ACT ) ... complete response letter from the U.S. Food and ... (NDA) for the fixed-dose combination (FDC) of nebivolol ... Photo - http://photos.prnewswire.com/prnh/20130124/NY47381LOGO ... of a complete response letter, Actavis remains committed ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... , NEW YORK, ... research report is available in its catalogue: , ... Analysis , http://www.reportlinker.com/p0164271/Multiple-Myeloma-Therapeutics---US-Market-Trends--Analysis.html , Given ... push to develop efficient therapies and treatments to battle ...
... LAS ANGELES, December 2 Fountain Healthy ... programme of,regular updates to shareholders, keeping them informed of the ... business plan, as,well as to provide shareholders with regular updates ... , Fountain reports that it continues ...
Cached Medicine Technology:Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 2Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 3Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 4Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 5Reportlinker Adds Multiple Myeloma Therapeutics - US Market Trends & Analysis 6Fountain Healthy Aging Inc Business Update For Shareholders 2Fountain Healthy Aging Inc Business Update For Shareholders 3
(Date:12/25/2014)... The report “TS-1 (Colorectal Cancer) – Forecast ... treatment landscape, unmet needs, current pipeline and commercial opportunities ... drug which is typically used for treating colorectal cancer. ... treating gastric cancer and pancreatic cancer. TS-1 is composed ... first approved in 1999 in Japan for the treatment ...
(Date:12/25/2014)... New York (PRWEB) December 25, 2014 ... 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue ... reports. According to an Order issued in the U.S. ... the Court will convene an open conference on January ... and United States Courthouse in West Palm Beach, Florida. ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, iFitDress.com, the ... for women, has announced its new selection of black ... are on sale now; they are available at discounted prices, ... says, “The promotion will last for three weeks only. You ... market. Those who are interested in our new items can ...
(Date:12/25/2014)... December 26, 2014 Recently, Dylan Queen, ... has excitedly released its collection of discounted prom dresses, ... Percy, a senior spokesman of the company, the promotion ... this promotion is to expand the UK market. , ... several different colors, lengths, and styles: A-line strapless, empire ...
Breaking Medicine News(10 mins):Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... there are plenty of ways to look and feel younger through ... homework before jumping into a more permanent change. , ... ... priorities to today,s changed economy doesn,t necessarily mean going without. However, ...
... OBS Medical has entered into an agreement ... of medical malpractice for US hospitals, for Beazley ... to hospitals that implement OBS,s Visensia(R) patient monitoring ... by Frost and Sullivan as a 2008 North ...
... March 25 ULURU Inc. (NYSE Alternext: ULU) ... discuss the fourth quarter and year ended 2008 financial results ... 2009 at 10:00 a.m. Eastern Time.To participate in the conference ... 429-1388 (access code 9304#) five to ten minutes prior to ...
... Persons who purchased or paid for (in whole or in ... reimbursed for (in whole or in part) Paxil CR(R) in ... relief as part of a $28 million Proposed Settlement. The ... between April 1, 2002 and March 4, 2005 contained a ...
... part of long-term relationships, , , WEDNESDAY, March 25 (HealthDay ... in long-term relationships transition from a passionate romance to ... isn,t true. , Reporting in the March issue of ... that while the manic, obsessive feelings that come with ...
... March 25 An amazing medical discovery that provides ... is in the US and looking to make the ... Release, go to: http://www.prnewswire.com/mnr/bathmateus/37601/ Developed by engineers, originally ... US at www.bathmateus.com , the Bathmate Hydropump reverses ...
Cached Medicine News:Health News:Orange County Plastic Surgeon Warns: When It Comes To The Face And Body, The Best Deal Could Cost More 2Health News:OBS Medical's Visensia Patient Monitoring Technology Lowers Cost of Medical Malpractice Insurance 2Health News:ULURU Inc. Announces Conference Call to Discuss Financial Results for the Fourth Quarter and Year Ended December 31, 2008 and to Provide a Business Update 2Health News:Proposed Settlement Will Make Up to $28 Million Available to Individuals Who Purchased and Companies That Reimbursed for Paxil CR(R) 2Health News:Romantic Love Can Last 2Health News:Romantic Love Can Last 3Health News:Video: Bathmate Hydropump Poised to Replace Cialis, Levitra, and Viagra 2
Angled for easy insertion into side port incision for manipulation of nucleus. Flat, paddle like tip for placement in groove to crack the nucleus for emulsification....
Excellent during IOL insertion while pushing the trailing haptic into position. Gently curved shaft and round handle....
Angled shaft with 1.5 mm tip designed to efficiently perform the "Stop and Chop" technique. Round knurled handle. Most popular size or model....
Smaller than the kuglen hook, this manipulator offers excellent grasping or lifting of the nucleus. Blunt finger-like 0.5 mm two-prong tip. Round knurled handle with dull finish. Angled....
Medicine Products: